Phase II Study of Mifepristone (RU486) in Refractory Ovarian Cancer

Objective. A phase II study of Mifepristone (RU486) was conducted in patients with ovarian cancer whose tumors were resistant to cisplatin and paclitaxel, alone or in combination. Patients and Methods. Forty-four patients were accrued into this study. All had ovarian cancer that had become resistant...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2000-06, Vol.77 (3), p.429-432
Main Authors: Rocereto, Thomas F., Saul, Howard M., Aikins, James A., Paulson, James
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents, Phytogenic - pharmacology
Biomarkers, Tumor - analysis
CA-125 Antigen - analysis
Carcinoma - drug therapy
Carcinoma - pathology
Cisplatin - pharmacology
Drug Administration Schedule
Drug Resistance, Neoplasm
Female
Hormone Antagonists - administration & dosage
Hormone Antagonists - therapeutic use
Humans
Mifepristone - administration & dosage
Mifepristone - therapeutic use
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Paclitaxel - pharmacology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. A phase II study of Mifepristone (RU486) was conducted in patients with ovarian cancer whose tumors were resistant to cisplatin and paclitaxel, alone or in combination. Patients and Methods. Forty-four patients were accrued into this study. All had ovarian cancer that had become resistant to cisplatin and paclitaxel. Patients received Mifepristone 200 mg orally on a daily basis. Patients were followed by tumor size or CA-125 levels when there was no measurable disease. A dose reduction of Mifepristone was to occur in the event of grade 3/4 hematologic, GI, or liver toxicity, creatinine >2.5%, and grade 4 peripheral neuropathy. Results. Thirty-four patients were evaluable for response. Nine (26.5%) of these patients had a response to Mifepristone. Three(9%) patients had a complete response, and six (17.5%), a partial response. The response of one patient in each group was measured by CA-125 levels while the remainder had measurable disease. The response lasted 1 to 4 months in all but one patient. One patient continues to respond after more than 3 years. The major toxic effect was a rash and this was the major reason patients were removed from the study. Conclusion. Mifepristone has activity against ovarian cancer resistant to cisplatin and paclitaxel. The drug is well tolerated. Further studies need to be performed when this drug becomes more widely available in the United States.
ISSN:0090-8258
1095-6859
DOI:10.1006/gyno.2000.5789